A new company in Scotland, UK has secured £2.4 million from KHAN Technology Transfer Fund I (KHAN-I) and existing investor Cumulus Oncology to pursue research into candidate molecules targeting DNA damage response. Nodus Oncology Ltd was founded in September 2022 to develop inhibitors of proteins involved in the repair of cells with DNA damage.
